Investor Relations

Who is BrainsWay?

BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology.

The Company received marketing authorization from the U.S. Food and Drug Administration (FDA) for its products for a variety of patient populations, including in 2013 for patients with major depressive disorder (MDD), in 2018 for patients with obsessive-compulsive disorder (OCD), and in 2020 for patients with smoking addiction.

BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders.

Latest Releases

August 10, 2022

BrainsWay Reports Second Quarter 2022 Financial Results and Operational Highlights

Revenue Growth of 14% Year-over-Year in Q2 2022 Conference call to be held today, August 10, 2022, at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Aug. 10, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive

Read More

July 27, 2022

BrainsWay to Report Second Quarter Financial Results on August 10, 2022

BURLINGTON, Mass. and JERUSALEM, July 27, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its second quarter financial

Read More

June 28, 2022

BrainsWay Announces Insurance Coverage by Israeli Ministry of Health for the Treatment of Depression

The Company’s Groundbreaking Deep TMS™ Treatment is Included in Israel’s Health Basket of Essential Medical Services BURLINGTON, Mass. and JERUSALEM, June 28, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive

Read More

For more information please contact:

Tel: +1-844-386-7001
Tel: +972-2-647-6010
Email: ir@brainsway.com